Targeted Quantitative Mass Spectrometry Analysis of Protein Biomarkers From Previously Stained Single Formalin-Fixed Paraffin-Embedded Tissue Sections

被引:5
作者
Ackermann, Bradley L. [1 ]
Morrison, Ryan D. [2 ]
Hill, Salisha [2 ]
Westfall, Matthew D. [2 ]
Butts, Brent D. [1 ]
Soper, Michael D. [1 ]
Fill, Jeff A. [1 ]
Schade, Andrew E. [1 ]
Liebler, Daniel C. [2 ]
Gruver, Aaron M. [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46225 USA
[2] Protypia Inc, Nashville, TN 37027 USA
关键词
formalin-fixed tissue; mass spectrometry; quantitative proteomics; single section; PROTEOMICS; EXPRESSION; CANCER;
D O I
10.1016/j.labinv.2022.100052
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Formalin-fixed, paraffin-embedded tissues represent a majority of all biopsy specimens commonly analyzed by histologic or immunohistochemical staining with adhesive coverslips attached. Mass spectrometry (MS) has recently been used to precisely quantify proteins in samples consisting of multiple unstained formalin-fixed, paraffin-embedded sections. Here, we report an MS method to analyze proteins from a single coverslipped 4 -mm section previously stained with hematoxylin and eosin, Masson trichrome, or 3,3'-diaminobenzidine-based immunohistochemical staining. We analyzed serial unstained and stained sections from non-small cell lung cancer specimens for proteins of varying abundance (PD-L1, RB1, CD73, and HLA-DRA). Coverslips were removed by soaking in xylene, and after tryptic digestion, peptides were analyzed by targeted high-resolution liquid chromatography with tandem MS with stable isotope-labeled peptide standards. The low -abundance proteins RB1 and PD-L1 were quantified in 31 and 35 of 50 total sections analyzed, respectively, whereas higher abundance CD73 and HLA-DRA were quantified in 49 and 50 sections, respectively. The inclusion of targeted b-actin measurement enabled normalization in samples where residual stain interfered with bulk protein quantitation by colorimetric assay. Measurement coefficient of variations for 5 replicate slides (hematoxylin and eosin stained vs unstained) from each block ranged from 3% to 18% for PD-L1, from 1% to 36% for RB1, 3% to 21% for CD73, and 4% to 29% for HLA-DRA. Collectively, these results demonstrate that targeted MS protein quantification can add a valuable data layer to clinical tissue specimens after assessment for standard pathology end points.(c) 2022 United States & Canadian Academy of Pathology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数:6
相关论文
共 21 条
  • [1] [Anonymous], FOUNDATIONONE CDX SP
  • [2] DNA Yield From Tissue Samples in Surgical Pathology and Minimum Tissue Requirements for Molecular Testing
    Austin, Melissa C.
    Smith, Christina
    Pritchard, Colin C.
    Tait, Jonathan F.
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (02) : 130 - 133
  • [3] Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States
    Bruno, Debora S.
    Hess, Lisa M.
    Li, Xiaohong
    Su, Eric Wen
    Patel, Monaliben
    [J]. JCO PRECISION ONCOLOGY, 2022, 6
  • [4] High-throughput proteomics: a methodological mini-review
    Cui, Miao
    Cheng, Chao
    Zhang, Lanjing
    [J]. LABORATORY INVESTIGATION, 2022, 102 (11) : 1170 - 1181
  • [5] Clinical Application of Multiple Reaction Monitoring-Mass Spectrometry to Human Epidermal Growth Factor Receptor 2 Measurements as a Potential Diagnostic Tool for Breast Cancer Therapy
    Do, Misol
    Kim, Hyunsoo
    Yeo, Injoon
    Lee, Jihyeon
    Park, In Ae
    Ryu, Han Suk
    Kim, Youngsoo
    [J]. CLINICAL CHEMISTRY, 2020, 66 (10) : 1339 - 1348
  • [6] Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+breast cancer
    Farahmand, Saman
    Fernandez, Aileen, I
    Ahmed, Fahad Shabbir
    Rimm, David L.
    Chuang, Jeffrey H.
    Reisenbichler, Emily
    Zarringhalam, Kourosh
    [J]. MODERN PATHOLOGY, 2022, 35 (01) : 44 - 51
  • [7] METHOD OF THE YEAR Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry
    Gillette, Michael A.
    Carr, Steven A.
    [J]. NATURE METHODS, 2013, 10 (01) : 28 - 34
  • [8] Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry
    Haragan, Alexander
    Liebler, Daniel C.
    Das, Dimple M.
    Soper, Michael D.
    Morrison, Ryan D.
    Slebos, Robbert J. C.
    Ackermann, Bradley L.
    Fill, Jeff A.
    Schade, Andrew E.
    Gosney, John R.
    Gruver, Aaron M.
    [J]. LABORATORY INVESTIGATION, 2020, 100 (06) : 874 - 886
  • [9] Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues
    Kennedy, Jacob J.
    Whiteaker, Jeffrey R.
    Kennedy, Laura C.
    Bosch, Dustin E.
    Lerch, Melissa L.
    Schoenherr, Regine M.
    Zhao, Lei
    Lin, ChenWei
    Chowdhury, Shrabanti
    Kilgore, Mark R.
    Allison, Kimberly H.
    Wang, Pei
    Hoofnagle, Andrew N.
    Baird, Geoffrey Stuart
    Paulovich, Amanda G.
    [J]. CLINICAL CHEMISTRY, 2021, 67 (07) : 1008 - 1018
  • [10] Immunohistochemistry and mass spectrometry for highly multiplexed cellular molecular imaging
    Levenson, Richard M.
    Borowsky, Alexander D.
    Angelo, Michael
    [J]. LABORATORY INVESTIGATION, 2015, 95 (04) : 397 - 405